Syndax Pharmaceuticals, Inc. Revenue
Syndax Pharmaceuticals, Inc. (SNDX) reported Revenue of $72.79 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-04
- Syndax Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $72.79M, a 91.76% increase year-over-year.
- Syndax Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $64.86M, a 223.64% increase year-over-year.
- Syndax Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $68.73M, a 794.90% increase year-over-year.
- Syndax Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $45.87M, a 266.97% increase year-over-year.
- Syndax Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $172.35M, a 627.84% increase from fiscal 2024.
- Syndax Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $23.68M.
- Syndax Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $0.00.
- Syndax Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $72.79M 10-Q · filed 2026-08-04 | $137.65M 10-Q · filed 2026-08-04 | $206.38M derived: sum of 3 quarters · filed 2026-08-04 | $252.25M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $64.86M 10-Q · filed 2026-04-30 | $133.59M derived: sum of 2 quarters · filed 2026-04-30 | $179.46M derived: sum of 3 quarters · filed 2026-04-30 | $217.42M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $68.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $114.60M derived: sum of 2 quarters · filed 2026-02-26 | $152.56M derived: sum of 3 quarters · filed 2026-08-04 | $172.35M 10-K · filed 2026-02-26 |
| 2025-09-30 | $45.87M 10-Q · filed 2025-11-03 | $83.83M derived: sum of 2 quarters · filed 2026-08-04 | $103.62M 10-Q · filed 2025-11-03 | $111.55M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $37.96M 10-Q · filed 2026-08-04 | $57.75M 10-Q · filed 2026-08-04 | $65.68M derived: sum of 3 quarters · filed 2026-08-04 | $78.18M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $20.04M 10-Q · filed 2026-04-30 | $27.72M derived: sum of 2 quarters · filed 2026-04-30 | $40.22M derived: sum of 3 quarters · filed 2026-04-30 | $43.72M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $7.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $20.18M derived: sum of 2 quarters · filed 2026-02-26 | $23.68M derived: sum of 3 quarters · filed 2026-02-26 | $23.68M 10-K · filed 2026-02-26 |
| 2024-09-30 | $12.50M 10-Q · filed 2025-11-03 | $16.00M derived: sum of 2 quarters · filed 2025-11-03 | $16.00M 10-Q · filed 2025-11-03 | $16.00M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $3.50M 10-Q · filed 2025-08-04 | $3.50M 10-Q · filed 2025-08-04 | $3.50M derived: sum of 3 quarters · filed 2026-02-26 | $3.50M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-05 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-05 | $0.00 derived: sum of 2 quarters · filed 2024-11-05 | $0.00 10-Q · filed 2024-11-05 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-01 | $0.00 10-Q · filed 2024-08-01 | ||
| 2022-12-31 | $0.00 10-K · filed 2025-03-03 | |||
| 2021-12-31 | $126.58M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $138.95M derived: sum of 2 quarters · filed 2024-02-27 | $139.33M derived: sum of 3 quarters · filed 2024-02-27 | $139.71M 10-K · filed 2024-02-27 |
| 2021-09-30 | $12.38M 10-Q · filed 2022-11-03 | $12.75M derived: sum of 2 quarters · filed 2022-11-03 | $13.13M 10-Q · filed 2022-11-03 | $13.51M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $379.00K 10-Q · filed 2022-08-08 | $758.00K 10-Q · filed 2022-08-08 | $1.14M derived: sum of 3 quarters · filed 2022-08-08 | $1.52M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $379.00K 10-Q · filed 2022-05-09 | $759.00K derived: sum of 2 quarters · filed 2022-05-09 | $1.14M derived: sum of 3 quarters · filed 2022-05-09 | $1.52M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $380.00K 10-K · filed 2021-03-12 | $759.00K derived: sum of 2 quarters · filed 2021-11-15 | $1.14M derived: sum of 3 quarters · filed 2021-11-15 | $1.52M 10-K · filed 2023-02-28 |
| 2020-09-30 | $379.00K 10-Q · filed 2021-11-15 | $758.00K derived: sum of 2 quarters · filed 2021-11-15 | $1.14M 10-Q · filed 2021-11-15 | $1.52M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $379.00K 10-Q · filed 2021-08-09 | $758.00K 10-Q · filed 2021-08-09 | $1.14M derived: sum of 3 quarters · filed 2021-08-09 | $1.52M derived: sum of 4 quarters · filed 2021-08-09 |
| 2020-03-31 | $379.00K 10-Q · filed 2021-05-11 | $759.00K derived: sum of 2 quarters · filed 2021-05-11 | $1.14M derived: sum of 3 quarters · filed 2021-05-11 | $1.52M derived: sum of 4 quarters · filed 2021-05-11 |
| 2019-12-31 | $380.00K 10-K · filed 2021-03-12 | $759.00K derived: sum of 2 quarters · filed 2021-03-12 | $1.14M derived: sum of 3 quarters · filed 2021-03-12 | $1.52M 10-K · filed 2022-03-01 |
| 2019-09-30 | $379.00K 10-K · filed 2021-03-12 | $758.00K derived: sum of 2 quarters · filed 2021-03-12 | $1.14M 10-Q · filed 2020-11-05 | $1.52M derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-06-30 | $379.00K 10-K · filed 2021-03-12 | $758.00K 10-Q · filed 2020-08-06 | $1.14M derived: sum of 3 quarters · filed 2021-03-12 | $1.52M derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-03-31 | $379.00K 10-K · filed 2021-03-12 | $759.00K derived: sum of 2 quarters · filed 2021-03-12 | $1.14M derived: sum of 3 quarters · filed 2021-03-12 | $1.52M derived: sum of 4 quarters · filed 2021-03-12 |
| 2018-12-31 | $380.00K 10-K · filed 2020-03-05 | $759.00K derived: sum of 2 quarters · filed 2020-03-05 | $1.14M derived: sum of 3 quarters · filed 2020-03-05 | $1.52M 10-K · filed 2021-03-12 |
| 2018-09-30 | $379.00K 10-K · filed 2020-03-05 | $758.00K derived: sum of 2 quarters · filed 2020-03-05 | $1.14M 10-Q · filed 2019-11-07 | $2.33M derived: sum of 4 quarters · filed 2020-03-05 |
| 2018-06-30 | $379.00K 10-K · filed 2020-03-05 | $758.00K 10-Q · filed 2019-08-07 | $1.95M derived: sum of 3 quarters · filed 2020-03-05 | $2.26M derived: sum of 4 quarters · filed 2020-03-05 |
| 2018-03-31 | $379.00K 10-K · filed 2020-03-05 | $1.57M derived: sum of 2 quarters · filed 2020-03-05 | $1.88M derived: sum of 3 quarters · filed 2020-03-05 | $2.18M derived: sum of 4 quarters · filed 2020-03-05 |
| 2017-12-31 | $1.19M 10-K · filed 2019-03-07 | $1.50M derived: sum of 2 quarters · filed 2019-03-07 | $1.80M derived: sum of 3 quarters · filed 2019-03-07 | $2.11M 10-K · filed 2020-03-05 |
| 2017-09-30 | $305.00K 10-K · filed 2019-03-07 | $610.00K derived: sum of 2 quarters · filed 2019-03-07 | $915.00K 10-Q · filed 2018-11-05 | |
| 2017-06-30 | $305.00K 10-K · filed 2019-03-07 | $610.00K 10-Q · filed 2018-08-08 | ||
| 2017-03-31 | $305.00K 10-K · filed 2019-03-07 | |||
| 2016-12-31 | $1.22M 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |